ASCO Annual Meeting

Novel Combo Therapy Shows Promise in Certain Patients With Non-Hodgkin Lymphoma

June 6th 2021, 5:00pm

Article

Treatment with a novel combination therapy was associated with increased efficacy among patients with aggressive relapsed or refractory B-cell non-Hodgkin lymphoma and was also well tolerated.

‘Incredible’ That a One-Time Infusion of CAR-T Cell Therapy Induces Durable Responses in Acute Lymphoblastic Leukemia

June 6th 2021, 4:00pm

Video

Although recent data show how promising a single-infusion of a specific CAR-T cell therapy may be for patients with acute lymphoblastic leukemia, an expert from the Moffitt Cancer Center notes that more research is needed for those deemed too ill to receive the treatment.

Lenvima-Keytruda Combination May Show ‘Promising Antitumor Activity’ in Advanced Colorectal Cancer

June 6th 2021, 3:00pm

Article

More than half of patients with previously treated advanced colorectal cancer who were treated with Lenvima and Keytruda were alive at six months while maintaining a manageable safety profile.

Certain Patients with Prostate Cancer Continue to Tolerate Extended Nubeqa Treatment

June 6th 2021, 1:00pm

Article

Patients with nonmetastatic castration-resistant prostate cancer continued to tolerate long-term treatment with Nubeqa, allowing them to maintain their quality of life and remain on therapy.

Novel CAR-T Cell Therapy Produces Early and Deep Responses in Certain Patients with Multiple Myeloma

June 5th 2021, 8:00pm

Article

A single infusion of a novel CAR-T cell therapy was associated with early and deep responses to treatment among a certain group of patients with multiple myeloma.

Gavreto ‘Very Well Tolerated’ in RET Fusion-Positive Non-Small Cell Lung Cancer

June 5th 2021, 6:00pm

Article

Findings demonstrated that Gavreto could clinically benefit those with RET fusion-positive non-small cell lung cancer, including those who are treatment naïve.

Zejula May Improve Survival in Certain Ovarian Cancer Subgroups

June 5th 2021, 5:00pm

Article

Progression-free survival improved with Zejula compared with placebo in patients with BRCA-mutated ovarian cancer with no new safety signals.

Men of African Ancestry Less Likely to Receive Genomic Profiling Early During Prostate Cancer Treatment

June 5th 2021, 4:00pm

Video

The data, according to one of the study’s authors, are critical in understanding the disparities in prostate cancer.

Opdivo Combined with Yervoy or Chemo Improves Survival in Unresectable and Advanced Esophageal Cancer

June 5th 2021, 3:00pm

Article

Adding Opdivo to treatment with Yervoy or chemotherapy improved survival, compared with chemotherapy alone in patients with unresectable and advanced esophageal cancer.

Lynparza Following Standard of Care Treatments Effective in Some Patients with High-Risk Breast Cancer

June 5th 2021, 2:00pm

Article

Some patients with early HER2-negative breast cancer at high risk for disease recurrence achieved meaningful benefit with Lynparza after receiving standard of care therapies, such as surgery or chemotherapy.